PMCB · Insider Trading
PharmaCyte Biotech, Inc. Common Stock
Every open-market purchase and sale reported by PMCB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-17 | Wayne Remell Walker | Director | J | — | — |
| 2026-07-17 | Robert Weinstein | Director | J | — | — |
| 2026-07-17 | Michael M Abecassis | Director | J | — | — |
| 2026-07-17 | Jonathan Schechter | Director | J | — | — |
| 2026-04-02 | Jonathan Schechter | Director | A | +119,170 deriv. | — |
| 2026-04-02 | Robert Weinstein | Director | A | +119,170 deriv. | — |
| 2026-04-02 | Michael M Abecassis | Director | A | +119,170 deriv. | — |
| 2026-04-02 | Wayne Remell Walker | Director | A | +119,170 deriv. | — |
| 2026-01-07 | Jonathan Schechter | Director | Buy | +60,000 | +$48.23K |
| 2026-01-07 | Joshua Silverman | CEO and President | Buy | +100,000 | +$80.48K |
| 2025-12-12 | Jonathan Schechter | Director | MIXED | +82,500 | −$68.85K |
| 2025-12-12 | Robert Weinstein | Director | MIXED | +41,250 | −$34.42K |
| 2025-12-12 | Wayne Remell Walker | Director | MIXED | +20,625 | −$17.21K |
| 2025-12-12 | Michael M Abecassis | Director | MIXED | +20,625 | −$17.21K |
| 2025-12-12 | Joshua Silverman | CEO and President | MIXED | +316,250 | −$263.93K |
| 2024-07-17 | Michael M Abecassis | Director | A | +38,009 deriv. | — |
| 2024-07-17 | Wayne Remell Walker | Director | A | +38,009 deriv. | — |
| 2024-07-17 | Robert Weinstein | Director | A | +38,009 deriv. | — |
| 2024-07-17 | Jonathan Schechter | Director | A | +38,009 deriv. | — |
| 2023-11-22 | Joshua Silverman | Interim CEO, Interim President | A | +170,000 deriv. | — |
| 2023-11-22 | Wayne Remell Walker | Director | A | +61,248 deriv. | — |
| 2023-11-22 | Carlos Trujillo | Chief Financial Officer | A | +85,000 deriv. | — |
| 2023-11-22 | Jonathan Schechter | Director | A | +61,248 deriv. | — |
| 2023-11-22 | Robert Weinstein | Director | A | +61,248 deriv. | — |
| 2023-11-22 | Michael M Abecassis | Director | A | +61,248 deriv. | — |
| 2022-12-30 | Daniel Stuart Farb | Director | A | +125,000 deriv. | — |
| 2022-12-30 | Daniel Allen | Director | A | +125,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Joshua Silverman | CEO and President | 466,250 | $189.76K |
| Jonathan Schechter | Director | 192,500 | $78.35K |
| Robert Weinstein | Director | 41,250 | $16.79K |
| Michael M Abecassis | Director | 23,092 | $9.40K |
| Wayne Remell Walker | Director | 20,625 | $8.39K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PMCB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.